Veru Inc. (VERU): Price and Financial Metrics

Veru Inc. (VERU): $1.21

0.01 (+1.09%)

POWR Rating

Component Grades














  • VERU scores best on the Value dimension, with a Value rank ahead of 37.06% of US stocks.
  • The strongest trend for VERU is in Growth, which has been heading up over the past 177 days.
  • VERU ranks lowest in Stability; there it ranks in the 1st percentile.

VERU Stock Summary

  • With a year-over-year growth in debt of 400.33%, VERU INC's debt growth rate surpasses 95.77% of about US stocks.
  • Over the past twelve months, VERU has reported earnings growth of 661.92%, putting it ahead of 97.35% of US stocks in our set.
  • Revenue growth over the past 12 months for VERU INC comes in at -54.38%, a number that bests merely 3.97% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to VERU INC, a group of peers worth examining would be CDXS, SAGE, MRNS, PXLW, and ARQT.
  • Visit VERU's SEC page to see the company's official filings. To visit the company's web site, go to

VERU Valuation Summary

  • VERU's EV/EBIT ratio is -0.6; this is 109.09% lower than that of the median Healthcare stock.
  • Over the past 243 months, VERU's EV/EBIT ratio has gone up 10.6.

Below are key valuation metrics over time for VERU.

Stock Date P/S P/B P/E EV/EBIT
VERU 2023-03-24 4.0 2.3 -1.0 -0.6
VERU 2023-03-23 3.8 2.2 -0.9 -0.6
VERU 2023-03-22 4.1 2.3 -1.0 -0.6
VERU 2023-03-21 4.6 2.6 -1.1 -0.8
VERU 2023-03-20 5.0 2.8 -1.2 -0.9
VERU 2023-03-17 4.7 2.6 -1.1 -0.8

VERU Growth Metrics

    Its 3 year revenue growth rate is now at 151.39%.
  • The 5 year revenue growth rate now stands at 163.84%.
  • Its year over year net income to common stockholders growth rate is now at -5684.31%.
Over the past 52 months, VERU's revenue has gone up $11,862,531.

The table below shows VERU's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 27.72701 -73.38124 -114.2382
2022-09-30 39.35435 -47.505 -83.77602
2022-06-30 52.41218 -27.43297 -47.04789
2022-03-31 60.46558 -26.24523 -27.54518
2021-12-31 60.77767 -24.88806 -16.21333
2021-09-30 61.25953 -15.57102 7.394374

VERU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VERU has a Quality Grade of C, ranking ahead of 60.52% of graded US stocks.
  • VERU's asset turnover comes in at 0.473 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • INSM, MNKD, and REPH are the stocks whose asset turnover ratios are most correlated with VERU.

The table below shows VERU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.473 0.788 0.038
2021-03-31 0.540 0.756 0.193
2020-12-31 0.760 0.737 0.295
2020-09-30 0.750 0.723 -0.912
2020-06-30 0.691 0.684 -0.376
2020-03-31 0.716 0.696 -0.365

VERU Price Target

For more insight on analysts targets of VERU, see our VERU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.40 Average Broker Recommendation 1.3 (Strong Buy)

VERU Stock Price Chart Interactive Chart >

Price chart for VERU

VERU Price/Volume Stats

Current price $1.21 52-week high $24.55
Prev. close $1.20 52-week low $1.15
Day low $1.15 Volume 614,048
Day high $1.22 Avg. volume 2,488,513
50-day MA $3.64 Dividend yield N/A
200-day MA $9.18 Market Cap 97.85M

Veru Inc. (VERU) Company Bio

Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.

VERU Latest News Stream

Event/Time News Detail
Loading, please wait...

VERU Latest Social Stream

Loading social stream, please wait...

View Full VERU Social Stream

Latest VERU News From Around the Web

Below are the latest news stories about VERU INC that investors may wish to consider to help them evaluate VERU as an investment opportunity.

Veru Inc.'s (NASDAQ:VERU) recent 20% pullback adds to one-year year losses, institutional owners may take drastic measures

Key Insights Given the large stake in the stock by institutions, Veru's stock price might be vulnerable to their...

Yahoo | March 27, 2023

UPDATE 1-Veru to proceed with late-stage study of COVID pill despite FDA snub

Drug developer Veru Inc on Tuesday said it plans to proceed with a late-stage trial of its COVID-19 pill, weeks after the U.S. health regulator declined to authorize the oral drug to treat high-risk patients hospitalized with COVID-19. Veru plans to continue development of the oral drug, sabizabulin, in late-stage studies with high-risk hospitalized influenza patients and COVID-19 patients. Additionally, Veru will stop the development of two of its other cancer drug candidates - VERU-100 and zuclomiphene - which it was testing in mid-stage studies for various indications.

Yahoo | March 14, 2023

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12 pm ET. In this presentation, Veru's CEO plans to share the Company's curre

Yahoo | March 7, 2023

First Solar (FSLR) Stock Pops on Analyst Upgrade

First Solar (FSLR) stock rose on Friday after the solar power company got an upgrade and increased price target from UBS.

William White on InvestorPlace | March 3, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off Friday morning with a breakdown of the biggest pre-market stock movers traders need to keep an eye on!

William White on InvestorPlace | March 3, 2023

Read More 'VERU' Stories Here

VERU Price Returns

1-mo -67.82%
3-mo -77.08%
6-mo -89.50%
1-year -74.95%
3-year -63.00%
5-year -33.15%
YTD -77.08%
2022 -10.36%
2021 -31.91%
2020 158.21%
2019 139.29%
2018 22.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8941 seconds.